Lilly signs up to $2.75B AI drug discovery deal with Insilico
What's the deal? Eli LillyDealroom has a profile for this one. Try Dealroom → has signed a drug discovery partnership with Insilico Medicine, a Hong Kong-listed biotech that uses generative AI to design drugs end-to-end.
Under the deal, announced March 2026, Insilico receives $115 million upfront and is eligible for up to $2.75 billion in total payments including development, regulatory, and commercial milestones, plus tiered royalties. Lilly gains exclusive worldwide rights to a portfolio of preclinical programmes across multiple therapeutic areas.
The two companies have been collaborating since 2023. The expanded deal deepens that relationship: Lilly will also use Insilico's Pharma.AI platform — which spans target discovery to compound design — to pursue additional research programmes focused on targets of Lilly's choosing. The specific disease areas were not disclosed.
Why now? Lilly is flush with capital from its obesity drug franchise and is racing to find its next pipeline before that revenue cycle peaks. Chief executive Dave RicksDealroom has a profile for this one. Try Dealroom → has framed AI-accelerated drug discovery as the "Holy Grail" — and Lilly has backed that with action, building an Nvidia-powered supercomputer at its Indianapolis headquarters and opening a $1 billion research lab in San Francisco in January 2026.
Insilico, meanwhile, has the most credible track record in AI-native drug development. Its lead compound, rentosertib — the first drug in which both the target and the molecule were discovered by generative AI — showed positive Phase IIa results for idiopathic pulmonary fibrosis, published in Nature Medicine in June 2025. That proof of concept has made Insilico one of the most attractive AI drug discovery partners in the industry.
What could go wrong? The deal's headline value of $2.75 billion is almost entirely contingent on future milestones. The upfront $115 million is the only guaranteed payment, and most AI-designed drugs — like all drugs — will fail in later-stage trials. The specific programmes being licensed are at preclinical stage, meaning years of development and significant attrition risk lie ahead.
There is also a geopolitical dimension: the deal is the latest in a string of tie-ups between Western pharma majors and Chinese companies, a category facing growing scrutiny in Washington.
The signal: Big pharma is no longer treating AI drug discovery as an experiment — it is writing nine-figure cheques for it. Lilly's bet on Insilico signals that the industry believes generative AI can genuinely compress the drug development timeline, not just automate marginal tasks. With over 173 AI-discovered programmes now in clinical development globally, 2026 is shaping up as the year the technology faces its first large-scale real-world test.
Sources:
Insilico Medicine
PR Newswire
Fierce Biotech
Reuters
CNBC
South China Morning Post
Bloomberg
The Wall Street Journal
Image credit:
Insilico Medicine
J.V.
